Clearmind Medicine Inc. Logo

Clearmind Medicine Inc.

Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.

CMND | US

Overview

Corporate Details

ISIN(s):
CA1850534027
LEI:
Country:
United States of America
Address:
101-1220 WEST 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics. The company's primary objective is to commercialize regulated medicines to solve widespread, under-served health problems, with a lead program targeting Alcohol Use Disorder (AUD). Its core treatment candidate is based on the proprietary psychoactive molecule MEAI (5-Methoxy-2-aminoindane), which is currently undergoing Phase I/IIa clinical trials. Clearmind's research is protected by a robust intellectual property portfolio of 19 patent families, underpinning its mission to provide breakthrough treatments for AUD, binge behaviors, and other mental health conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Clearmind Medicine Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Clearmind Medicine Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Clearmind Medicine Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary GWPH
Gossamer Bio, Inc. Logo
Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.
United States of America GOSS
Grace Therapeutics, Inc. Logo
Develops improved drugs for rare neurological diseases using novel drug delivery technologies.
United States of America GRCE
A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.
South Korea 005250
GREEN CROSS WellBeing Corporation Logo
Develops personalized nutrition solutions, from prescription injections to supplements & cosmetics.
South Korea 234690
Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain GRF

Talk to a Data Expert

Have a question? We'll get back to you promptly.